Contribute Try STAT+ Today

Moderna Therapeutics, biotech’s highest-profile and most richly funded startup, is losing another key executive, struggling to retain talent despite the company’s unwavering promise that it’s on pace to change the face of medicine.

Dr. Stephen Kelsey, head of Moderna’s oncology division, is leaving the company to work at a biotech startup in California, according to people familiar with the matter. Each spoke on condition of anonymity, citing strict nondisclosure agreements.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.